PAS
ATRA icon

Point72 Asia (Singapore)’s Atara Biotherapeutics ATRA Stock Holding History

Point72 Asia (Singapore)’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-3,603
Closed -$48K – 873
2024
Q4 		$48K Buy
+3,603
New +$38K 0.01% 516
2024
Q3 		– Sell
-6,292
Closed -$53.5K – 963
2024
Q2 		$53.5K Buy
+6,292
New +$94.6K 0.01% 635

Other funds holding ATRA

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.57B AUM 26.96% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Point72 Asia (Singapore)'s ATRA Position: Q1 2025 in Review

Point72 Asia (Singapore) sold out of Atara Biotherapeutics (ATRA) in Q1 2025, closing a stake of 3,603 shares — an estimated $48K sold.

Point72 Asia (Singapore) first reported a position in ATRA in Q2 2024 and held it in 2 quarters. The position peaked at $53.5K in Q2 2024. 37 funds tracked by Wall St. Rank hold ATRA as of Q1 2025.

  • Point72 Asia (Singapore) reported no remaining Atara Biotherapeutics position as of Q1 2025 after selling out during the quarter.
  • Point72 Asia (Singapore) sold 3,603 Atara Biotherapeutics shares in Q1 2025, an estimated $48K.
  • Point72 Asia (Singapore) first reported a position in Atara Biotherapeutics in Q2 2024 and held it in 2 quarters.
  • Point72 Asia (Singapore)'s Atara Biotherapeutics position peaked at $53.5K in Q2 2024.
  • 37 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q1 2025.

Based on Point72 Asia (Singapore)'s 13F filing for Q1 2025, filed 15 May 2025.